text:
Wait for me! By David B
Two Hooded Mergansers at Inglewood Bird Sanctuary. The male has fallen behind and is trying to catch up to his mate.
Mar 16, 2011
Family Fun, Candid Captures, Must-See Spots
Inglewood Bird Sanctuary, Sanctuary road
Get the lowdown on Inglewood Bird Sanctuary
Like this Photo
Suggested Itineraries
Sports & Adventureview details
Many know Calgary as the gateway to Rocky mountain adventures. You'll find just as much excitement as a participant or spectator within the city limits.
Unexpectedview details
What do ballet, tapas and fly fishing have in common? They're but three of the hidden surprises you'll find within Calgary's city limits.
Report this Photo
Is this photo inappropriate? If so, please let us know.Report ImageCancel


text:
"I use a lot of repetition. And it becomes a filmic way of talking because as you put the same image after the other, even though it's the exact identical image, everyone sees something changing from one image to the next."
Download Now
The Season One Screening Guide can be downloaded as PDF files: of the entire guide, or by thematic section.
Full Guide
Download: Season 1 Screening Guide [4.8 MB]
Individual Thematic Sections
Artists: Margaret Kilgallen, Sally Mann, Barry McGee, Pepón Osorio, and Richard Serra
Introduction: Laurie Anderson
Download: Place Screening Guide [2.3 MB]
Artists: John Feodorov, Ann Hamilton, Shahzia Sikander, and James Turrell
Introduction: Beryl Korot with S. Epatha Merkerson
Download: Spirituality Screening Guide [1.8 MB]
Artists: Louise Bourgeois, Maya Lin, Kerry James Marshall, and Bruce Nauman
Introduction: William Wegman with Steve Martin
Download: Identity Screening Guide [2.4 MB]
Artists: Matthew Barney, Michael Ray Charles, Mel Chin, and Andrea Zittel
Introduction: Barbara Kruger with John McEnroe
Download: Consumption Screening Guide [2.3 MB]
Art21 Education
- Events & Initiatives
- Tools for Teaching
- Guides
- Activities
- Creative Chemistries: Radical Practices for Art + Education
- On the ART21 Magazine
- On Contemporary Art
- Archive

subset: commoncrawl


text:
Taiwan Semiconductor Manufacturing, the largest third-party contract manufacturer in the world, has reportedly declined offers from both Apple and Qualcomm, who were looking for exclusive capacity to meet demand for their own products. Rumors of Apple tapping Taiwan Semiconductor have persisted for years, with nothing materializing. The iPhone maker could potentially be interested in using Taiwan Semi to produce its custom mobile processors for future iDevices, which would displace its current supplier, Samsung.
Apple is the most influential company in technology and has delivered market-smashing returns. However, with the impending release of the iPhone 5 and Apple TV on the horizon, the stakes have never been higher for the company. If you're looking for a recommendation on how to play Apple, along with continuing updates and guidance on the company whenever news breaks, we've created a brand-new report that details when to buy and sell Apple. To get started, just click here now.


text:
The work of linoleum block printer, Jeff Granett, will be on display from January through March 2012. You can already get a "sneak peek" of his work, as he has assembled a calendar of his mythical beasts that is on display right now in our store. In fact, we have these fanciful calendars for sale for only $15, if you are looking for an original, local gift for someone on your holiday list. Here's what the author has to say about his upcoming exhibit:
The major theme of the pictures I am displaying at this time is "Mythic Beasts." To be mythic, such animals must be imaginary and relate to human life experiences and aspirations, sometimes in a sub-conscious way. Some of the beasts depicted come from Greek or Roman mythology. Others come from the mythology rattling around in my own brain. Either way, their stories go beyond what we know. Apologies to Joseph Campbell's ghost. These pictures were parts of my 2012 calendar.
Other pictures which Jeff will have on display were printed over the last 10 years. Viewers are encouraged to come and offer their comments and personal perspectives at his Second Friday Reception which will be held on February 10th from 6:00 to 8:30. All are welcome!


text:
Snowboards, All Brands - Women'sWomens Snowboards, All Brands from the Proboardshop. We stock all of the hottest snowboards and related snowboarding equipment for the ladies. Our shipping department is a finely tuned machine and returns or exchanges are painless.We've been rocking out Womens Snowboards since 1982. You've tried the rest, now try the best, Proboardshop.
Please refine here More in the Outlet Shop.
- Brand: Burton
- Color: Orange
Snowboards, All Brands More in the Outlet Shop.
Burton Lip-Stick Snowboard - Women's
Size: 152cmReg: $479.95 On Sale: $335.97
Burton Socialite Snowboard - Women's
Size: 138cm, 142cm, 147cm, 151cmReg: $469.95 On Sale: $375.95
Burton Sweet Tooth Snowboard 2014 - Women'sReg: $449.95 On Sale: $314.97
Size: 141cm, 145cm, 148cm


text:
Cindy Crawford's Bikini Body Shows Off Her Bikini Body in January
Bless. More »
Bless. More »
The resemblance is uncanny! More »
Heaven is just a place on Earth. More »
Like mother, like daughter. More »
Some people are saying she's the next Kendall Jenner. More »
This is what it sounds like when the Kardashians cry. More »
Kendall Jenner just added another job to her growing résumé. More »
Party like it's 1999!
… More »
Following the leaders.
… More »
Cindy Crawford posted this makeup-free (and wrinkle free) selfie to celebrate her 50th (Feb. 20th), and fans can't help but wonder about the model's skin care routine and secrets that keep her looking so young. … More »
It seems as though the supermodel isn't retiring after all. … More »
It's the end of an era.
… More »


text:
Not sure where to put this, but needed to get it off my chest.
I go to my GP's clinic to get bt's done. My fs is tracking my estrogen levels and things have been moving slowly, so I've had quite a few done over the last few weeks. Each time I've seen my GP in passing and we've waved, occasionally his stuck his head around the corner to have a bit of a chat. Today he told the lady taking my blood to get me to come to his room afterwards. So I waited around for a bit.
Anyway. He asked me if I was angry at him, because last time I hadn't smiled and been happy to see him. Had he done something wrong? I assured him I was just tired and upset from the meds I'm on. He patted his belly and asked how it was going (IVF) and what all the bt's were for, so I explained but he stopped listening to me. He asked for my phone number, and when I said reception had it, and why did he want it he asked if I didn't want him to have it. He obviously didn't want to get it from them. He asked what I was doing this weekend, and I said I was working. What am I doing next weekend? Don't know, dp will be in and I keep all that time free for him. When will I have a weekend off? I work on a roster, so that's ages away. What's wrong, don't I want him to call me? Umm, freaking no! Didn't say that though. Just diverted away from that. Went to leave and he opened his arms wide for a hug. This isn't the first time he's hugged me, but usually I'm good at deflecting it and he backs off for a few visits. I convince myself I'm overreacting and imagining things, and forget about it. About a year ago he tried to arrange for our families to do some things together, but I'd completely pushed that away. Am I freaking for a reason, or does it sound like he's just pushing to be friends? He's not Australian, so maybe he's not picking up on the social cues?
This is the best Drs clinic in a 40 min drive, and I don't want to leave it. But i don't need to go for personal reasons often, just to get my ad script so I suppose I could do that anywhere. Thing is, I'm a disability support worker, and most of my clients go to him so I don't want to make waves and have things be awkward for work visits. It's almost impossible to get Drs to accept my clients onto their books, and I won't do anything to jeopardize that.
I don't know what I want from posting this, except maybe to get it out. I'm very unsettled and not sure how to handle it.


text:
Night, Again
Edited by Linh Dinh
Format: Paperback
Normal Price: $28.45
Your Price: $25.61 AUD, inc. GST
Shipping: $7.95 per order
You Save: $2.85! (10% off normal price)
Plus...earn $1.28 in Boomerang Bucks
Availability: Available, ships in 8-11 days
Night, Again by Linh Dinh
Book DescriptionChoice Academic Book of the Year - a ground breaking collection now including two new stories. Praised for its documentary importance and literary brilliance when it was first published in 1996, and now updated with two new stories, "Night", "Again" offers the unique opportunity to see the Vietnamese through their own eyes and surprises readers with its playfully ironic portraits.
Buy Night, Again book by Linh Dinh from Australia's Online Bookstore, Boomerang Books.
Book DetailsISBN: 9781583227060
(210mm x 140mm x 13mm)
Pages: 224
Imprint: Seven Stories Press,U.S.
Publisher: Seven Stories Press,U.S.
Publish Date: 3-Jan-2006
Country of Publication: United States
Other Editions...
Books By Author Linh Dinh
Love Like Hate, Paperback (February 2010)
A dysfunctional family saga that doubles as a portrait of Vietnam in the last half century.
Blood and Soap, Paperback (May 2004)
A seamless collection of short stories from the author of the acclaimed "Fake House."
Fake House, Hardback (November 2000)» View all books by Linh Dinh
In his first collection of short stories, Dinh explores the weird, atrocious, fond, ongoing intimacies between post-war Vietnam and the United States, introducing characters linked by a common past and driven by an intense and angry energy.
» Have you read this book? We'd like to know what you think about it - write a review about Night, Again book by Linh Dinh and you'll earn 50c in Boomerang Bucks loyalty dollars (you must be a member - it's free to sign up!)
Author Biography - Linh Dinh
Linh Dinh is an accomplished author, poet and translator. He was awarded a Pew Fellowship in 1993 and hosted in Certaldo, Italy, as a guest of the International parliament of Writers and Cities of Asylum. He has written two collections of short stories, Fake House and Blood and Soap, and two books of poems, All Around What Empties Out and American Tatts. His work has been anthologised in Best American Poetry 2000, Best American Poetry 2004 and Great American Prose Poems from Poe to the Present.
Facebook Page | Twitter | Google+ | Bulletin e-Newsletter | Blog | RSS
Become a Member | Book Lists | Recently Released | Coming Soon | Fast Delivery Books
Bestselling Books: Our Current Bestsellers | Australia's Hottest 1000 Books | Bestselling Fiction | Bestselling Crime Mysteries and Thrillers | Bestselling Non Fiction Books | Bestselling Sport Books | Bestselling Gardening and Handicrafts Books | Bestselling Biographies | Bestselling Food and Drink | Bestselling History | Bestselling Travel Books | Bestselling School Textbooks & Study Guides | Bestselling Children's General Non-Fiction | Bestselling Young Adult Fiction | Bestselling Children's Fiction | Bestselling Picture Books | Top 100 US Bestsellers
For: Schools | Organisations | Libraries | Publishers | Authors | Book Clubs | Bloggers | Affiliates
About Us | Contact Us | Help Desk | Security | Privacy | Terms of Use | Copyright
Phone: 1300 36 33 32 (9am-5pm Mon-Fri AEST) - International: +61 2 9960 7998 - Online Form
Address: Boomerang Books, 878 Military Road, Mosman Junction, NSW, 2088
© 2003-2017. All Rights Reserved. Eclipse Commerce Pty Ltd - ACN: 122 110 687 - ABN: 49 122 110 687
For every $20 you spend on books, you will receive $1 in Boomerang Bucks loyalty dollars. You can use your Boomerang Bucks as a credit towards a future purchase from Boomerang Books. Note that you must be a Member (free to sign up) and that conditions do apply.


text: The Magic is BackAlex Belth5/13/13 9:38amEditPromoteGo to permalinkWell, not yet. But for Greg Prince, co-author of the fine site, Faith and Fear in Flushing, the glass of Mets fandowm is always half-full. Check out this Q&A with Greg as he talks about volume 1 of a 4-part book sereis: The Happiest Recap.


text: Seller: europeantiqueshop (1,263) 100%, Location: Holland, Ships to: US, CA, AU, Item: 201730328549 handelshuis1 Store Increase traffic to your listing with Auctiva's FREE Scrolling Gallery. A Wrought-Iron / Wood Round 6 light Chandelier, from circa 1950. The chandelier will be rewired for to use in US. It measures 27" wide 41" tall (inluding chain). The Priority shipping costs from Europe to USA (store to door) are $FREE. Check out my other items for a combine shipping! Powered by eBay Turbo Lister On Apr-01-07 at 15:01:10 PDT, seller added the following information: On Apr-11-16 at 14:32:56 PDT, seller added the following information: Material: Cast Iron / wood, Original or Reproduction: Original, Style: castle, Product Type: Chandeliers, Fixtures & Sconce, Region or Style: French


text:
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
"Our strong financial performance is a direct result of the success of our technology platform and business strategy. We and our partners are advancing our large and growing pipeline of 19 drugs in development. Our partnership strategy not only allows our drugs to move forward effectively toward the market but also provides us with significant short and intermediate term financial benefits that enable us to continue to advance the technology and fill the pipeline with more exciting new drugs," said B. Lynne Parshall, COO and CFO of Isis.
Upcoming Key Milestones
Financial Results
On a GAAP basis, Isis reported a loss from operations of $4.8 million and $5.5 million for the three and six months ended June 30, 2009, respectively, compared to income from operations of $1.1 million and a loss from operations of $5.2 million for the three and six months ended June 30, 2008, respectively. Additionally, Isis reported a net loss of $2.9 million and net income of $168.9 million for the three and six months ended June 30, 2009, respectively, compared to its net loss of $3.7 million and $9.5 million for the same periods in 2008. Isis' financial results in 2009 reflect higher expenses associated with the expansion of the Company's programs as discussed in more detail in the "Operating Expenses" section below, offset in part, by an increase in revenue recognized in 2009 from Isis' corporate partnerships compared to 2008. Also, Ibis' revenue and expense are included in Isis' 2008 financial results as discontinued operations and are not included in Isis' 2009 financial results. In addition, Isis' 2009 financial results reflect the sale of Ibis. Please refer to the reconciliation of pro forma and GAAP measures, which is explained later in this release.
As a result of selling Isis' diagnostic subsidiary, Ibis Biosciences, to Abbott Molecular Inc. (AMI) in the first quarter of 2009, Isis is reporting Ibis' financial results as discontinued operations. Accordingly, Isis has presented all periods of Ibis' operating results in Isis' financial statements separately as discontinued operations. The discontinued operations line in the first six months of 2009 also includes the $171.8 million gain that Isis recognized on the sale net of taxes. A reconciliation summarizing the adjustments made to reflect the changes to Isis' 2008 historical statement of operations appears later in this release.
Revenue for the three and six months ended June 30, 2009 was $31.0 million and $62.6 million compared to $29.7 million and $48.1 million in the same periods of 2008. The substantial increase in Isis' revenue is primarily due to an increase in revenue from the Company's collaboration with Genzyme because the three and six months ended June 30, 2008 only included one month of amortization of the $175 million license fee that Isis received in June 2008.
Isis' satellite companies also contributed to the increase in the Company's revenue:
Isis' revenue fluctuates based on the nature and timing of payments under agreements with the Company's partners, including license fees, milestone-related payments and other payments, such as the bulleted items above. Assuming no new transactions, the Company's revenue will decrease when the $50 million upfront payment Isis received from Ortho-McNeil-Janssen in 2007 is fully amortized in the third quarter of this year.
Operating Expenses
On a pro forma basis, operating expenses for the three and six months ended June 30, 2009 were $32.3 million and $61.8 million compared to $25.1 million and $46.4 million for the same periods in 2008. Consistent with Isis' guidance, the higher expenses in 2009 were primarily due to the expansion of the Company's clinical development programs, including additional expenses associated with the broad Phase 3 clinical program for mipomersen, the lead drug in Isis' cardiovascular franchise, expenses for Regulus as it builds its core team and expenses related to the Company's expansion of its drug discovery activities into new therapeutic areas. On a GAAP basis, Isis' operating expenses from continuing operations for the three and six months ended June 30, 2009 were $35.8 million and $68.0 million compared to $28.6 million and $53.2 million for the same periods in 2008, including non-cash compensation expense related to stock options of $3.6 million and $6.3 million for the three and six months ended June 30, 2009 and $3.5 million and $6.8 million for the same periods in 2008. During the remainder of 2009, Isis' operating expenses will increase modestly as Isis continues its research and development activities described above.
Interest Expense
In 2009, Isis adopted FASB Staff Position No. APB 14-1 (FSP 14-1) for its 2 5/8% convertible notes, which required Isis to assign a value to its convertible debt without considering the conversion feature. As a result, Isis is recording its convertible debt at a discount, which Isis is amortizing over the expected life of the debt as additional non-cash interest expense. FSP 14-1 required retrospective application to all periods presented. Accordingly, the amount of interest expense Isis recorded in its statement of operations for the three and six months ended June 30, 2009 increased by $1.7 million and $3.3 million compared to an increase of $1.5 million and $3.0 million for the same periods in 2008. This new standard did not impact Isis' cash, cash equivalents and short-term investments but decreased the carrying value of Isis' $162.5 million convertible notes to $121.5 million and $118.0 million at June 30, 2009 and December 31, 2008, respectively, with corresponding increases to shareholders' equity. A reconciliation summarizing the adjustments made to reflect the changes to Isis' 2008 historical statement of operations appears later in this release.
Net Income (Loss) from Continuing Operations, Net of Income Tax Benefit
Net loss from continuing operations for the second quarter of 2009 was $3.8 million compared to net income from continuing operations of $463,000 for the same period in 2008. For the six months ended June 30, 2009 and 2008, net loss from continuing operations was $4.6 million and $5.6 million, respectively.
Even though Isis finished the first six months of 2009 with a net loss from continuing operations, Isis had taxable income, which is primarily a result of the significant upfront payments that the Company received from its strategic alliance with Genzyme in 2008 and the gain it recognized on the sale of Ibis to AMI earlier this year. Accounting rules require Isis to record an income tax benefit of $656,000 on a line called "Income Tax Benefit" as part of its financial results from continuing operations because it will be using the tax benefits generated from its current year loss from continuing operations to offset a portion of its taxable income.
Isis' net loss from continuing operations also included a $2.5 million gain on investments that Isis recognized in the second quarter of 2009 when it sold the stock it held in OncoGenex. OncoGenex' stock price increased significantly in the second quarter of 2009 after announcing encouraging data from its clinical studies of OGX-011 and OGX-427. This gain further demonstrates the value that Isis is recognizing from its satellite company strategy.
Net Income (Loss) from Discontinued Operations
The net income (loss) from discontinued operations represents the operating results of Ibis that are presented separately in Isis' financial statements as a result of the sale of Ibis to AMI in January 2009. Net income from discontinued operations in the first six months of 2009 primarily consists of the $202.5 million gain less income taxes. Accounting rules require Isis to allocate its 2009 tax expense between discontinued operations and continuing operations in its Consolidated Statement of Operations. Since the sale of Ibis to AMI was a discrete event that occurred in the first quarter of 2009, the accounting rules required Isis to record the total amount of its estimated income tax expense for discontinued operations in the first quarter of this year. Further, Isis was required to gross up this amount by the projected annual tax benefit it expects to record as part of its loss from continuing operations in 2009, which is described above. This means that in addition to the tax expense for the gain on the sale of Ibis, discontinued operations also includes the tax expense for other timing differences, which principally consists of the timing difference associated with the upfront funding Isis received from Genzyme. Accordingly, Isis recorded tax expense of $30.7 million in discontinued operations in the first quarter of 2009. A reconciliation summarizing the adjustments made to reflect the changes to Isis' 2008 historical statement of operations appears later in this release.
Net Income (Loss)
Isis reported a net loss of $2.9 million for the three months ended June 30, 2009 and net income of $168.9 million for the six months ended June 30, 2009, compared to a net loss of $3.7 million and $9.5 million in the three and six months ended June 30, 2008. Basic and diluted net loss per share for the three months ended June 30, 2009 was $0.03 per share compared to $0.04 per share for the same period in 2008. Basic and diluted net income per share for the six months ended June 30, 2009 was $1.73 per share and $1.56 per share, respectively, compared to basic and diluted net loss per share of $0.10 for the same period in 2008. The improvement in Isis' net income and net income per share for the first half of 2009 over the same period in 2008 was primarily due to the gain Isis recognized when it sold Ibis to AMI.
Balance Sheet
As of June 30, 2009, Isis had cash, cash equivalents and short-term investments of $637.5 million compared to $491.0 million at December 31, 2008 and had consolidated working capital of $519.7 million at June 30, 2009 compared to $393.7 million at December 31, 2008. Isis received $175 million from AMI in the first quarter of 2009 for its sale of Ibis, which resulted in the significant increases in both of these amounts. In addition, during the first half of 2009, Isis received more than $31 million in cash from its corporate partnerships, including the $11 million upfront license fee that Isis received from its recently announced licensing and collaboration agreement with Alnylam.
Regulus Therapeutics
Regulus' revenue for the three and six months ended June 30, 2009 was $1.1 million and $1.8 million compared to $656,000 and $748,000 for the same periods in 2008. The increase was primarily related to revenue from its collaboration with GSK, including the $500,000 discovery milestone payment that Regulus received from GSK for demonstrating a pharmacological effect in immune cells by specific microRNA inhibition.
Excluding non-cash compensation expense related to stock options, operating expenses for Regulus were $2.7 million and $5.5 million for the three and six months ended June 30, 2009 compared to $1.7 million and $2.8 million for the same periods in 2008. The increase is primarily related to Regulus' continued efforts to build its team to support its internal microRNA programs and its GSK collaboration. Regulus generated a loss from operations, excluding non-cash compensation expense related to stock options, of $1.6 million and $3.8 million for the three and six months ended June 30, 2009 compared to $1.1 million and $2.1 million for the same periods in 2008.
Business Highlights
"During the last quarter, we and Genzyme made great progress regarding mipomersen on two important fronts, advancing the clinical development program and refining our regulatory strategy. We reported positive top-line results from a Phase 3 study of mipomersen in the largest, placebo-controlled Phase 3 study in homozygous FH patients. We reported that the study met its primary endpoint with a 25% reduction in LDL-C after 26 weeks of treatment with mipomersen versus 3% for placebo and all of its secondary endpoints in a highly statistically significant manner. We are very pleased with the performance of mipomersen in this study. These data are a significant milestone in the clinical development of mipomersen and support our efforts to make the drug available to patients in need," said Ms. Parshall.
"In addition to reporting data from the first of our Phase 3 trials for mipomersen, we and Genzyme refined and communicated the regulatory path for mipomersen in the United States and Europe. While the strategy continues to evolve, Genzyme plans to file the first NDA for mipomersen in the U.S. for homozygous FH in the second half of 2010, with a similar filing in Europe shortly afterwards. Data from our Phase 3 study in severe hypercholesterolemia patients should be available at the time of these U.S. submissions and may provide the basis for a broader indication. A potential second filing in Europe will involve a broader patient population, namely heterozygous FH patients. This strategy ensures that mipomersen will reach the patients who need the drug the most first, and provide commercial experience with mipomersen as we broaden our indication to larger patient populations, such as heterozygous FH patients. We have now completed enrollment in the mipomersen Phase 3 study in heterozygous FH patients, the second of our four Phase 3 studies, and we expect to report the data from this study in the first half of 2010," continued Ms. Parshall.
"During the last quarter, we and our partners participated prominently in several scientific conferences, including ASCO and ADA, highlighting the versatility and broad applicability of antisense drugs to inhibit targets that could offer new avenues to treat disease, including cancer and type 2 diabetes. In addition to our clinical programs, we have active programs in many different therapeutic areas as well as established academic relationships with industry and academic leaders that expand our research capabilities. With the efficiency of our drug discovery technology we can broadly evaluate and conduct preliminary research on a vast array of new targets, so that we can add new drugs to our pipeline each year," added Ms. Parshall.
"In summary, it has been an eventful and promising first half of the year. Our financial position ensures that we can continue to invest our resources in filling the pipeline and continuing to move our drugs forward toward the market. We have the technology, the expertise and the momentum to realize the full potential of antisense as a drug discovery technology," concluded Ms. Parshall.
Drug Development Highlights
Mipomersen, the most advanced drug in Isis' cardiovascular pipeline, is being evaluated in a broad Phase 3 program in patients who cannot adequately control their cholesterol levels with current therapies and who need new treatment options.
Isis' partnered pipeline continues to mature as antisense drugs that Isis' satellite companies are developing advance in clinical development.
Isis' collaborators presented new clinical data on drugs in Isis' partnered oncology franchise at this year's American Society of Clinical Oncology (ASCO) annual meeting.
Isis and its collaborators highlighted new antisense therapeutic programs and targets to treat metabolic diseases, including obesity, at the American Diabetes Association (ADA) scientific sessions.
Isis partnered with non profit foundations to pursue new treatments for debilitating diseases, such as severe neurodegenerative diseases.
Isis was awarded a grant from the Michael J. Fox Foundation's Therapeutic Development Initiative program for the discovery and development of an antisense drug for the treatment of Parkinson's Disease.
Isis benefits from its partners as they advance RNA-based technologies and develop drugs that incorporate Isis' technology resulting in financial benefits as these assets mature.
Conference Call
At 08:30 a.m. Eastern Time today, August 6, Isis will conduct a live webcast conference call to discuss this earnings release and related activities. Interested parties may listen to the call by dialing 866-788-0538 and refer to passcode "isis2009," or access the webcast at www.isispharm.com. A webcast replay will be available for a limited time at the same address.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.
This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, the financial position and outlook for Isis as well as Regulus, its majority-owned subsidiary, and the therapeutic and commercial potential of the Company's technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2008, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.
Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.
Reconciliation of GAAP to Pro Forma Basis
As illustrated in the Selected Financial Information in this press release, pro forma operating expenses, pro forma loss from operations and pro forma net income (loss) were adjusted from GAAP to exclude compensation expense related to stock options, which are non-cash. Isis has regularly reported non-GAAP measures for operating expenses and loss from operations as pro forma results. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Isis reports these pro forma results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Isis' pro forma results is consistent with how Isis' management internally evaluates the performance of its operations.
-- Report full data from a Phase 3 study evaluating mipomersen in homozygous Familial Hypercholesterolemia (FH) patients; positive top line data was reported in May 2009 -- Report data from additional mipomersen studies in other patient populations -- Report data from a Phase 2 study evaluating ISIS 113715 in combination with sulfonylureas in patients with type 2 diabetes -- Begin clinical trials on at least one additional drug in 2009; clinical trials already initiated on three drugs this year -- Expand pipeline by moving at least two additional drugs into development in 2009; one new drug has already moved into development this year
SOURCE Isis Pharmaceuticals, Inc.
You May Also Like


text:
Final Ministry record details
God Al's been bombing since 03,04. He needs to lay Ministry to rest FOR GOOD unless he can make another solid Industrial album to finish the game, not Slayer wannabe music (nothing against Slayer) like the "Bush Trilogy" or Relapse. Although they still put on a killer show from what I hear...Nice Nick Cave pun tho lol "From Her to Eternity"
title just screams ministry
Digging: Power Trip - Nightmare Logic
Relapse was a disappointment, but I hope this will be better.
How many times they will release "our last album"??? Hope the new one will be better than Relapse also.
Haha, yeah, this is their third "last" album. I hope that out of those fun, creative sessions came out stronger tracks.
Relapse was poor but I have hopes of a new album which has some consistency
So let me get this straight, The Last Sucker was his "last" album. Then he came found out with Relapse which I thought was his return but apparently was his last album again? Either Al or the author of this article are confusing as fuck. So is this going to be his last album because of Mike Scaccia's death?
And for the record, Relapse was a solid album and doesn't differ much from his past 10 years worth of releases.
Al needs to get back with Jello and make a new Lard album
Nah Al is probably the confused one here, anyway I have no hope for this
I'll listen
yeah the author is right, Al said Relapse would be the last, and before that the Last Sucker was supposed to be as well
Digging: Blood Command - Ghostclocks
So let me get this straight, The Last Sucker was his "last" album. Then he came found out with Relapse which I thought was his return but apparently was his last album again? Either Al or the author of this article are confusing as fuck. So is this going to be his last album because of Mike Scaccia's death?
This is their third "final" album.
They must do a "final" tour after their "final" albums along with Judas Priest...
Rio Grande Blood ruled
This is their third "final" album.
Fuck, is he trying to pull a Kiss or something?
can't wait, love Ministry
I bet he'll do one more reunion album after with Paul Barker (if Al doesn't die first). I hope he does (release another w Barker). (shit.)
Anyone interested in Ministry should check out Paul Barker's solo work. I like post-Barker thrash Ministry a lot, but solo Barker is even better, almost as good as Mind / Psalm era Ministry.
• Michael Gira Accused of Rape• R.I.P. David Bowie• R.I.P. Lemmy• The Story So Far's vocalist dropk..• Scott Weiland dead at 48 • Brand new Brand New Single• Killswitch Engage debut new single• Rush drummer retires• Deftones stream new single• Riverside guitarist dies
• R.I.P. Toshio Nakanishi• Knuckle Puck debut new single• Remo Drive premiere new singles• Uneven Structure release video• Havok vs. Fake News in third sing..• Ghost Bath Announce Album• New Seether single, album• Ulver announce new album• New Acceptance Album Stream• New While She Sleeps single• Celldweller's "Electric Eye"• New Chainsmokers ft. Coldplay• New Shade Empire song• Yowie premiere new single; 3rd al..• At the Drive-In to release new re..» see all news
Bands: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


text: As of this month, Qantas' low-cost airline Jetstar is offering iPads for rent as in-flight entertainment for A$10 per flight in Australia and Asia. The in-flight iPads are loaded with movies, music, magazines, books and games. Jetstar marketing manager David May was quoted in Business Traveller as saying, "if the trial works we want to put them on every aircraft because they're so much slimmer and lighter than our existing units and I imagine we will be seeing many other airlines follow suit."


text:
|Visitors Now:
|Total Visits:
|Total Stories:
|Story Views
|Last Hour:
|Last 24 Hours:
Pump Up Your Book Presents Meredith Michelle's POP STAR Cover Reveal November 21, 2016 Inside the Book: Title: Pop Star Author: Meredith Michelle Publisher: Lyrical Shine Genre: Romance Format: Ecopy CHOOSE HOW FAR YOU WANT TO GO . . . You are Honey Noble, this month's Rock N Roll Magazine cover star, with a platinum debut album and swarms of devoted "Honey Bees." Life has never been sweeter—or crazier, as you juggle a cross-country tour (traveling on your luxury Airstream tour bus), a clothing line, fabulous endorsements, and a relationship with gorgeous former boy-bander, Crispin Hershey. But rumors are swirling about Crispin's flirtation with pop's bad girl, Trixie
Read More


text:
Spells And Charms in Raleigh, NC
Merry Meet! My name is Phelan. I am a white witch located in Atlanta, GA. I specialize in customizing rituals and spells for "Spells And Charms" or "Spells And Magic". All rituals are customized to the needs, desires and goals of my client. Please feel free to call me at 678-918-3333 or create an account if you need help with email readings to reveal clues about your past, present and future or psychic readings by phone or in person.
I can help you with email readings to reveal clues about your past, present and future or psychic readings by phone or in person in Raleigh, NC, pick up the phone and call me today!
I use white magic to heal a clients situation, contact me today to heal the heart of your situation.
Feel free to browse through our website and create an account if you would like to know more about the services I offer or about Spells And Charms, Spells And Magic and Spells Curses Hexes Black Magic More. Remember, I am located in Atlanta, GA you can call me Mon-Fri from 1-9 pm EST, I can be of assistance to you in person or by phone.
Blessed Be, Phelan
Spells And Charms | Effective Love Spells | Raleigh, NC


text:
ItraMAS Technology Sdn. Bhd.
LED Lighting, Commercial Led Lighting, Home Led Lighting
Q-RAY™ DownLED luminaire acts as a direct replacement for conventional down light. This is an easy 'plug & play' model -- as easy as pulling out the old & replace with the new one! The Q-RAY™ DownLED is widely used in commercial buildings, airports, showrooms, hallways as well as homes. The lower power consumption means that it minimizes carbon emission to protect the environment. It has no mercury content, no heat generated through the light beam which means that it will protect any valuables on display.
Print this page
Create your free Hotfrog business profile
Follow Hotfrog on:
Share on:
Hotfrog Small Business Hub


text:
I've heard a lot of Survivors call other Survivors some pretty horrible things over the years, but for some reason, Mr. Farty really stands out for me. There's nothing particularly ingenious about it. Jane simply took Marty's name, realized her good fortune in that it rhymed with "farty," and rolled with it. But, see, the average insulter would have stopped right then and there and called it a day — sufficiently pleased with their comedic word play. But not Jane. By simply adding a "Mr." prefix, she took it to a whole different level. There's just something about Mr. Farty that is so insanely absurd that you have no choice but to love it. Seriously, Mr Farty. It just has a certain je ne sais quoi about it. And the fact that the game of Survivor has reduced 56-year-old Jane to busting out kindergarten-level insults is truly amazing. (Go to any playground and say the words "Mr. Farty" and I guarantee you they will think you are the funniest person on the face of the planet. And you know what? YOU WOULD BE!) But this was just one in a long line of insults in what is becoming an increasingly testy season of Survivor. Let's take it from the top.
To Read More Click Here.


text:
Is Gong Cha incorrect or missing key business information? Update your Hotfrog listing today.
Contact details
Are these details correct?
Hotfrog Philippines provides information regarding Gong Cha in Taguig Metro Manila. Gong Cha is located at 4/F, SM Aura Premier, McKinley Parkway Corner 26th Street SM Aura Premier, Taguig Metro Manila and provides Food And Dining services. Contact them on (02) 579 6846.
Opening hours
Mon 11:00-12:00, 14:00-16:00, 18:00-19:00; Tue 11:00-12:00, 14:00-20:00; Wed 11:00-14:00, 16:00-21:00; Thu 10:00-21:00; Fri 10:00-12:00, 15:00-21:00; Sat 9:00-21:00; Sun 10:00-21:00
Is Gong Cha in 4/F, SM Aura Premier, McKinley Parkway Corner 26th Street SM Aura Premier, Taguig Metro Manila your business? Claim your listing and attract more leads by adding more content, photos and other business details.
We have more Food And Dining services in Taguig Metro Manila available on Hotfrog Philippines. You can update your search for Taguig Food And Dining by location, keyword or service options.
Small Business Hub
Sharing tips, ideas and advice to help grow your small business.
Create your free Hotfrog business profile
Follow Hotfrog on:
Share on:
Hotfrog Small Business Hub


text:
P & P Technology
EMI shielding, knitted wire mesh, knitted mesh
There are six ranges within P & P Technology's Knitted Mesh Range: Knitted Mesh: (KP Range) When evenly compressed between two metallic contact surfaces, provide high levels of EMI shielding. The KP range are available in four basic wire types - Aluminium, Monel, TCS and Stainless Steel. Elastomer-Cored Knitted Wire Mesh: (KE Series) In comparison with 'solid' mesh types, elastomer-cored knitted wire meshes have a high degree of recovery so are more suitable for use on doors and covers that are regularly open and closed. Twinstrip: (KC Series) Combination of knitted or cored mesh gasket with a non-conductive environmental seal. Knitted Mesh with Carrier: (KM Series) Suitable for use on covers, door frames and other apertures where the surrounding metalwork is either heavy duty or insufficiently rigid, and needs a well anchored, robust gasket that will not be affected by the stresses and shearing action imposed on conventional twinstrip gaskets.Knitted Mesh Bandages: (KW Series) Tubular form knitted stocking supplied in flat tape form and available in four basic wire types: Stainless Steel, Monel, Aluminium and TCS.Compressed Mesh: (KR Series) Compressed mesh profiles are used as gland rings, grounding buttons, EMP gaskets, magnetron seals and other applications where a high density mesh is required.
Print this page
Create your free Hotfrog business profile
Follow Hotfrog on:
Share on:
Hotfrog Small Business Hub


text:
Great Britain born 1937
Two peppers
Place made:
London, Greater London, England
Materials & Technique: prints, Intaglio Colour etching, softground etching printed from two copper plates. Support: White, mould-made, Arches paper.
Manufacturer's Mark: No manufacturers mark.
Impression: 20/100
Edition: Edition of 100; 23 proofs.
Publisher: Petersburg Press Ltd
Place Published: London
Date Published: 1973


text:
'LBD' 53mm Polarized Sunglasses
Product not available
Have questions?
Chat with us or call 1.888.282.6060.
HideDetails & Care
Just glowing with rock-star style, classic sunglasses feature shapely frames and smart polarized lenses for color-true clarity.
- 53mm lens width; 17mm bridge width; 134mm temple length.
- 100% UV protection.
- Plutonite® lenses.
- O-Matter™ frames.
- By Oakley; made in Italy.


text:
Today, after waiting 2 hours for my landlord to leave so I could take a shit in peace, I sat down on the toilet. The doorbell immediately rang. It was my landlord, who wanted to let me know that he had just backed into my car. FML
By chubbs / Wednesday 28 May 2014 21:07 / United States - Vacaville
Top comments
Too many negative votes, comment buried. Show the comment
seems like every time 'that word' is mentioned, that comment gets downvoted
No it's downvoted because it makes no sense. Maybe if a priest took a dump on OP the comment makes sense, literally, but in this case, no.
It is a bit shit to be honest though..
did op at least finish taking a shit?
Piece of Shit landlord...
Nobody laughs at these any more.
Too many negative votes, comment buried. Show the comment
or he gets sued for parking his car in the wrong place by his landlord. and then he loses all his money
why would u assume OP parked in the wrong spot? maybe the landlord is a shitty driver. ever think of that?
I think 11 was making a situation that could possibly be spouted by the landlord so that he doesn't have to pay.
Too many negative votes, comment buried. Show the comment
Loading data…


text:
The plight of teachers whose federal grants are suddenly -- and in thousands of cases wrongfully -- converted to delinquent loans is a problem that education bureaucrats know about but have chosen to ignore, although the issue is beginning to percolate in Congress.
"We have a real problem here," said Rep. David Joyce (R-Ohio) in a recent letter to Secretary of Education Arne Duncan. "Programs to help ease the burden of teacher loans all too often don't accomplish that goal. Instead, they end up leaving many qualified candidates with costlier loan payments and more debt. It's time to create a more effective approach that gives teachers the support they need to make a difference in the lives of kids everywhere."
The TEACH Grant Program was established by Congress to encourage more teachers to go to "high-needs" schools and teach subjects that are critically important to students' success. But many teachers who have lived up to their end of the deal now find themselves burdened with additional debt.
"This is an advertised federal program to help people become teachers. In reality, it's a for-profit scam," said David West, a South Carolina teacher whose grant was converted to a loan because of a minor administrative error, as reported in a recent ConsumerAffairs story.
2,252 errors & counting
The accounts of West and other young teachers are no surprise to the Government Accountability Office (GAO), which reported in May that, as of September 2014, at least 2,252 TEACH grants had been erroneously converted to loans. "Education officials said they now monitor the [loan] servicer more closely and plan to review all of the nearly 36,000 of the program's grant-to-loan conversions, but the agency has not systematically reviewed the cause of the errors," GAO said.
West and other teachers say their grants of $4,000 or more -- awarded to them for teaching in "high-needs" schools -- were converted to delinquent interest-bearing loans even though the teachers were doing everything they were required to do but had made simple administrative errors in filling out the annual paperwork the grants require.
The teachers appealed the conversions, but their appeals were denied, something else that would not come as news to the GAO examiners. In their March 2015 report, they wrote that the Department of Education "established a dispute process to address concerns about TEACH grants converted to loans in error; however, GAO found that Education and the servicer provide incomplete and inconsistent information to recipients about the availability of and criteria for disputing conversions."
GAO said such conduct is "inconsistent with federal internal control standards that highlight effective external communication."
Agreed but did nothing
GAO recommended that the Education Department "examine why erroneous TEACH grant-to-loan conversions occurred, disseminate information on the TEACH grant-to-loan dispute process, and establish program performance measures."
The department said it agreed with GAO's recommendations, but that is little comfort to the thousands of teachers who find themselves rewarded for their efforts by being plunged into debt and threatened in harsh letters telling them their credit ratings will be affected and their income tax refunds may be seized.
No one has bothered to tell them of the 2,252 errors or to assure them their cases will get a second look.
The TEACH grants are administered by FedLoan, a Pennsylvania state agency that is part of a larger agency whose primary responsibility is providing grants to Pennsylvania students. A spokesman for that agency said he could not comment and referred inquiries to the Education Department, which did not respond to repeated requests for comment.
Congress takes note
The issue is drawing the attention of several members of Congress, however. On May 7, Joyce joined with Sens. Orrin Hatch (R-Utah) and Mark Warner (D-Va.) and Rep. Derek Kilmer (D-Wash.) in a letter to Secretary of Education Arne Duncan noting the problems with the TEACH grants and other programs and saying they "look forward to working with [him]" to improve the programs.
"Unfortunately, our current federal grant and loan forgiveness programs for teachers are a jumble of uncoordinated programs that are often too difficult to navigate. We have a responsibility to our teachers, students, families and taxpayers to do better," Sen. Warner said.
Duncan, one of the longer-serving members of President Obama's cabinet, announced earlier this month that he plans to step down in December. Duncan, a former basketball player, said he plans to return to Chicago and "continue to involve the work of expanding opportunity for children" but gave no indication he would do anything about the TEACH grants.


text:
The ultimate goal of this project is to identify molecular mechanisms of pathogenesis and potential therapeutic targets that are common to Spinocerebellar ataxias (SCAs). These are a group ~30 genetically heterogeneous neurodegenerative disorders that share neuropathological and clinical features such as atrophy of the cerebellum and loss of motor coordination and balance. Recent data points to unsuspected links among inherited ataxias. First, a protein- protein-interaction network for inherited ataxias revealed that many ataxia-causing proteins share interacting partners. Second, dAtaxin-2 (an orthologue of the protein responsible for SCA2) is a major modifier of Ataxin-1[82Q]-induced neurotoxicity in a Drosophila model of SCA1. Together, these observations suggest that SCAs, and perhaps other inherited ataxias may share molecular mechanisms of pathogenesis in addition to similar neuropathology and clinical features. This hypothesis predicts that SCAs have common genetic modifiers and potential therapeutic targets that remain unknown. Testing this hypothesis requires a thorough comparison of genetic modifiers and mechanisms of pathogenesis among different inherited ataxias. A genetic approach will be employed to identify modifiers of neurotoxicity caused by expanded Ataxin-1, Ataxin-2 and Ataxin-7, the proteins responsible for SCA1, SCA2 an SCA7. The work proposed here will address the following specific aims: 1) To investigate the molecular mechanisms by which partial loss of dAtaxin-2 function suppresses Ataxin-1[82Q]-induced neurodegeneration. 2) To screen the ataxia interactome for genetic modifiers of Ataxin-1[82Q]-induced neurotoxicity. 3) To test the Ataxin-1[82Q] genetic modifiers and the ataxia interactome in Drosophila models of SCA2 and SCA7. 4) To validate the genetic interaction between Ataxin-2 and Ataxin-1 in a knock-in mouse SCA1 model. Since these extensive comparative studies are impractical with mammalian models, we will use Drosophila models for the majority of the analysis and mouse models for validation of key interactions. The suppressors of neurodegeneration identified as a result of this work may directly point to specific therapeutic targets. These basic studies are prerequisite to developing therapies for these neurodegenerative disorders for which there are no effective treatments.
The work in this proposal is aimed towards revealing mechanisms of pathogenesis and identifying potential therapeutic targets in Spinocerebellar ataxias. These basic studies are a prerequisite to developing therapies for these neurodegenerative disorders for which there are no effective treatments.
|Romero, Eliana; Cha, Guang-Ho; Verstreken, Patrik et al. (2008) Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm. Neuron 57:27-40
|Sofola, Oyinkan A; Jin, Peng; Qin, Yunlong et al. (2007) RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 55:565-71
|Al-Ramahi, Ismael; Perez, Alma M; Lim, Janghoo et al. (2007) dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. PLoS Genet 3:e234
|Kaltenbach, Linda S; Romero, Eliana; Becklin, Robert R et al. (2007) Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 3:e82
|Al-Ramahi, Ismael; Lam, Yung C; Chen, Hung-Kai et al. (2006) CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem 281:26714-24
|de Haro, Maria; Al-Ramahi, Ismael; De Gouyon, Beatrice et al. (2006) MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum Mol Genet 15:2138-45
|Tsuda, Hiroshi; Jafar-Nejad, Hamed; Patel, Akash J et al. (2005) The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. Cell 122:633-44
|Chen, Hung-Kai; Fernandez-Funez, Pedro; Acevedo, Summer F et al. (2003) Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113:457-68